FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Humoral antibody response of 10 horses after vaccination aga...
Equine veterinary journal2020; 53(4); 826-833; doi: 10.1111/evj.13363

Humoral antibody response of 10 horses after vaccination against African horse sickness with an inactivated vaccine containing all 9 serotypes in one injection.

Abstract: African horse sickness (AHS) is a devastating viral disease of equids that was first recorded in 1327. Currently, prevention and control of the disease are based on attenuated vaccines and midge control. It has been shown that attenuated Orbivirus vaccines are not always safe as they may reverse to virulence. Objective: In the Emirate of Dubai, a vaccination experiment was carried out with an inactivated AHS vaccine produced at the Central Veterinary Research Laboratory (CVRL), Dubai, UAE to investigate the humoral antibody response of AHS-naïve horses to this vaccine. Our vaccination experiment was performed to establish an AHS vaccine bank in the UAE to protect horses from the disease in case of an outbreak. Therefore, CVRL established an inactivated AHS vaccine containing all nine serotypes which induce high neutralising antibodies. Methods: A total of 10 horses kept in a desert isolation area were subcutaneously and intramuscularly vaccinated with an inactivated vaccine containing all nine AHS serotypes previously isolated from Kenyan horse fatalities. Primary immunisation was followed by two booster immunisations 4 weeks and 6 months apart. After 13 months, an annual booster was administered. Methods: Blood samples were regularly withdrawn for ELISA and virus neutralisation testing. Additionally, EDTA blood was tested every second day for 14 days post each vaccination for the presence of AHS virus or its RNA. Results: Results show that ELISA and virus neutralising antibodies appeared after the first booster, declined after 4-6 months and therefore three vaccinations and an annual vaccination are necessary to achieve high protective virus neutralising antibodies. Conclusions: No challenge infection was carried out due to the lack of a safe facility in the UAE. Conclusions: Before more advanced AHS vaccines become a reality, inactivated vaccines containing all nine serotypes should be used as they produce high ELISA and neutralising antibodies.
© 2020 EVJ Ltd.
Get Full Text
Publication Date: 2020-10-29 PubMed ID: 33011979DOI: 10.1111/evj.13363Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article presents a study on the antibody response of horses to an inactivated vaccine against African Horse Sickness (AHS). The study uses a vaccine containing all nine serotypes and concludes that such vaccines generate high neutralising antibodies and are a viable preventative measure.

Objective and Background

  • The study was conducted in the Emirate of Dubai with the aim of investigating the humoral antibody response of AHS-naïve horses to an inactivated AHS vaccine.
  • The reason for this research was to create an AHS vaccine bank in the United Arab Emirates to protect horses from the disease during an outbreak.
  • The research was also conducted against the backdrop of the knowledge that attenuated Orbivirus vaccines can reverse into virulence, making them unsafe.

Methodology

  • 10 horses kept in a desert isolation area were used for the experiment.
  • The horses were vaccinated through subcutaneous and intramuscular injections with an inactivated vaccine that contains all nine AHS serotypes.
  • The primary immunisation was followed by two booster immunisations — at 4 weeks and then 6 months following the initial vaccination.
  • An annual booster was administered after 13 months.
  • Blood samples were regularly withdrawn from the horses for Enzyme-Linked Immunosorbent Assay (ELISA) and virus neutralisation testing.
  • EDTA blood of the horses was tested every other day for a fortnight post each vaccination for the presence of AHS virus or its RNA.

Results

  • ELISA and virus neutralising antibodies began appearing after the first booster immunisation.
  • However, the antibodies declined after 4-6 months.
  • Therefore, the study recommends three vaccinations and an annual booster vaccination to maintain a high level of protective virus neutralising antibodies.

Conclusions

  • A challenge infection was not used in this research due to the lack of a safe facility in the United Arab Emirates.
  • Until more advanced AHS vaccines are developed, inactivated vaccines that contain all nine serotypes should be used since they yield high ELISA and neutralising antibodies.

Cite This Article

APA
Wernery U, Rodriguez M, Raghavan R, Syriac G, Miriam Thomas M S, Elizabeth SK, Federico Ronchi G, Muhammed R, Patteril NA, Joseph S. (2020). Humoral antibody response of 10 horses after vaccination against African horse sickness with an inactivated vaccine containing all 9 serotypes in one injection. Equine Vet J, 53(4), 826-833. https://doi.org/10.1111/evj.13363

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 53
Issue: 4
Pages: 826-833

Researcher Affiliations

Wernery, Ulrich
  • Central Veterinary Research Laboratory, Dubai, UAE.
Rodriguez, Marina
  • Central Veterinary Research Laboratory, Dubai, UAE.
Raghavan, Rekha
  • Central Veterinary Research Laboratory, Dubai, UAE.
Syriac, Ginu
  • Central Veterinary Research Laboratory, Dubai, UAE.
Miriam Thomas M, Shruti
  • Central Veterinary Research Laboratory, Dubai, UAE.
Elizabeth, Shyna K
  • Central Veterinary Research Laboratory, Dubai, UAE.
Federico Ronchi, Gaetano
  • Istituto Zooprofilattico Sperimentale, dell'Abruzzo e del Molise "G. Caporale", Teramo, Italy.
Muhammed, Rubeena
  • Central Veterinary Research Laboratory, Dubai, UAE.
Patteril, Nissy A
  • Central Veterinary Research Laboratory, Dubai, UAE.
Joseph, Sunitha
  • Central Veterinary Research Laboratory, Dubai, UAE.

MeSH Terms

  • African Horse Sickness / prevention & control
  • African Horse Sickness Virus
  • Animals
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antibody Formation
  • Horse Diseases / prevention & control
  • Horses
  • Kenya
  • Serogroup
  • Vaccination / veterinary
  • Vaccines, Inactivated
  • Viral Vaccines

Grant Funding

  • Central Veterinary Research Laboratory (CVRL)

References

This article includes 45 references
  1. Coetzer J, Guthrie AJ. African horse sickness. In: Coetzer J, Tustin RC, editors. Infectious diseases of livestock. 2nd ed. England: Oxford University. Volume 2; 2004:1231-46.
  2. St Zientara X. African horse sickness. In: Lefèvre P-C, Blancou J, Chermette R, Uilenberg G, editors. Infectious and parasitic diseases of livestock. Volume 1. Lavoisier; 2010; p. 689-704.
  3. Fernández PJ, White WR. African horse sickness. In: Fernández PJ, White WR, editors. Atlas of transboundary animal diseases. OIE, 2010; p. 11-8.
  4. Wernery U, Joseph S, Rodriguez M, Raghavan R, Dyer B, Spendrup S. African horse sickness fever in vaccinated horses. Short communication. J Equine Vet Sci 2020;88:102967.
  5. Crafford JE, Lourens CW, Smit TK, Gardner IA, MacLachlan NJ, Guthrie AJ. Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines. Vaccine 2014;32(29):3611-6.
  6. Guthrie AJ, Quan M. African horse sickness. In: Mair TS, Hutchinson RE, editors. Infectious diseases of the horse. Cambridgeshire, UK: A peer-reviewed publication, 2009; p. 72-82.
  7. Aiello SE, Moses MA, Allen DG. Merck veterinary manual. Kenilworth, USA: Merck and Co., Inc., Bluetongue, 2016; p. 738-41.
  8. Salama SA, El Husseini MM, Abdalla SK. 3rd and 4th Ann. Rep. US AHS Project 169, Cairo 1979 and 1980; 55-69: 91-98.
  9. Diouf ND, Etter E, Lo MM, Lo M, Akakpo AJ. Outbreaks of African horse sickness in Senegal and methods of control of the 2007 epidemic. Vet Rec 2013;172(6):152-9.
  10. OIE. Manual of diagnostic tests and vaccines for terrestrial animals. African horse sickness. 8th ed. OIE, 2018:1237-52.
  11. van Vuuren M, Penzhorn BL. Geographic range of vector-borne infections and their vectors: the role of African wildlife. Rev Sci Tech Off Int Epiz 2015;34(1):139-49.
  12. OIE WAHIS (World Animal Health Information System). 2019. https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer=MapFullEventReport&reportid=30236
  13. OIE WAHIS (World Animal Health Information System). 2020. https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer=MapEventSummary&reportid=33912
  14. Attoui H, Mohd JF. Zoonotic and emerging orbivirus infections. Rev Sci Tech Off Int Epiz 2015;34(2):353-61.
  15. Zientara S, Weyer CT, Lecollinet S. African horse sickness. Rev Sci Tech Off Int Epiz 2015;34(2):315-27.
  16. Lubroth J. African horse sickness and the epizootic in Spain in 1987. Equine Pract 1988;10:26-33.
  17. Oura CA. Possible role for domestic dogs in the spread of African horse sickness virus. Vet Rec 2018;713-4.
  18. O'Dell N, Arnot L, Janisch CE, Steyl JCA. Clinical presentation and pathology of suspected vector transmitted African horse sickness in South African domestic dogs from 2006 to 2017. Vet Rec 2018;182(25):715.
  19. Weyer CT, Grewar JD, Burger P, Rossouw E, Lourens C, Joone C. African Horse Sickness caused by genome reassortment and reversion to virulence of live, attenuated vaccine viruses, South Africa, 2004-2014. Emerg Infect Dis 2016;22(12):2087-96.
  20. Otieno OGE, Amimo JO. Molecular epidemiology of African Horse Sickness in Kenya. African Horse Sickness Conf., Proc. Abstract, Nairobi Kenya 2018;33-4.
  21. Dennis SJ, Meyers AE, Hitzeroth J, Rybicki EP. African Horse Sickness: a review of current understanding and vaccine development. Viruses 2019;11(9):844.
  22. Wernery U, Joseph S, Elizabeth ShK, Patteril NG, Wernery R, Spendrup S. Production of an African Horse Sickness killed vaccine containing all 9 serotypes. J Equine Vet Sci 2016;39:S101-S102.
  23. Dubourget P, Preaud JM, Detraz N, Lacoste F. Production and quality control of an industrial inactivated vaccine against AHS type IV. In: Walton TE, Osburn BI, editors. Bluetongue, african horse sickness and related orbiviruses. Boca Raton, Florida: CRC Press, 1993;874-86.
  24. House J, Lombard M, Dubourget P, House C, Mebus C. Efficacy of an inactivated African horse sickness serotype 4 vaccine. In: Walton TE, Osburn BI, editors. Bluetongue, African horse sickness and related orbivirus. Proc. Of the Sec. Int. Symposium. Boca Raton, Florida, USA: CRC Press, 1992; p. 891-5.
  25. Ronchi GF, Ulisse S, Rossi E, Franchi P, Armillotta G, Capista S. Immunogenicity of two adjuvant formulations of an inactivated African horse sickness vaccine in guinea-pigs and target animals. Vet Ital 2012;48(1):55-76.
  26. OIE. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Tests for sterility and freedom from contamination of biological materials intended for veterinary use. 8th ed; Paris, France: OIE; p. 109-122.
  27. Mirchamsy H, Taslimi H. Inactivated African Horse Sickness virus cell culture vaccine. Immunology 1968;14(1):81-8.
  28. Bahnemann HG. The inactivation of foot-and-mouth disesase virus by ethylenimine and propylenimine. Zentralbl Veterinarmed B 1972;20(5):356-60.
  29. Bahnemann HG. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine 1990;8(4):299-303.
  30. Rodriguez M, Joseph S, Pfeffer M, Raghavan R, Wernery U. Immune response of horses to inactivated African horse sickness vaccine. BMC Vet Res 2020;16(1):1-13.
  31. Hamblin C, Graham SD, Anderson EC, Crowther JR. A competitive ELISA for the detection of group-specific antibodies to African horse sickness virus. Epidemiol Infect 1990;104:303-12.
  32. Lelli R, Molini U, Ronchi GF, Rossi E, Franchi P, Ulisse S. Inactivated and ajuvanated vaccine for the control of the African horse sickness virus serotype 9 infection: evaluation of efficacy in horses and guinea-pig model. Vet Ital 2013;49(1):89-98.
  33. Guthrie AJ, MacLachlan NJ, Joone C, Lourens CW, Weyer CT, Quan M. Diagnostic accuracy of a duplex real-time reverse transcription quantitative PCR assay for detection of African horse sickness virus. J Virol Methods 2013;189:30-5.
  34. Maree S, Paweska JT. Preparation of recombinant African horse sickenss virus Vp7 antigen via a simple method and validation of a VP7 based indirect ELISA for the detection of group-specific IgG antibodies in horse sera. J Virol Methods 2005;125:155-65.
  35. Van Dijk AA. African Horse Sickness vaccine development. In: Wernery U, Wade JF, Mumford JA, Kaaden O-R, editors. Equine infectious diseases, 8th edn. Newmarket, UK: R and W Publications; 1999; p. 261-5.
  36. Dennis SJ, O’Kennedy MM, Rutkowska D, Tsekoa T, Lourens CW, Hitzeroth II. Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses. Vet Res 2018;49(1).
    doi: 10.1186/s13567-018-0600-4google scholar: lookup
  37. Wernery U, Joseph S, Raghavan R, Spendrup S, Dyer B. Serological evidence on the role of the Onderstepoort attenuated African horse sickness vaccine by induction of antibody response to a nine serotype containing CVRL inactivated African horse sickness vaccine. East African Journal of Veterinary and Animal Science 2020; (in press).
  38. Hamblin C, Mellor PS, Graham SD, Hooghuis H, Montejano RC, Cubillo MA. Antibodies in horses, mules and donkeys following monovalent vaccination against African horse sickness. Epidemiol Infect 1991;106:365-71.
  39. De la Poza F, Marin Lopez A, Castillo-Olivares J, Calvo-Pinilla E, Ortego J. Identification of CD8T cell epitopes in VP2 and NS1 proteins of African horse sickness virus in IFNAR (-/-) mice. Virus Res 2015;210: 149-53.
  40. Pretorius A, Van Kleef M, Van Wyngaarft W, Health J. Virus-specific CD8 + T-cells detected in PBMC from horses vaccinated against African horse sickness virus. Vet Immunol Immunopathol 2012;146:81-6.
  41. Mellor PS, Hamblin C. African horse sickness. Vet Res 2004;35:445-66.
  42. Lefèvre P-C, Mellor PH, Saegerman Cl. Bluetongue. In: Lefèvre P-C, Blancou J, Chermette R, Uilenberg G, editors. Infectious and parasitic diseases of livestock. Corsica, France: Lavoisier; p. 663-88, 1.
  43. European Medicines Agency. mail@emea.europa.eu. 2009. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/bluevac-btv8#authorisation-details-section. Accessed March 6, 2018
  44. Alberca B, Bachanek-Bankowska K, Cabana M, Calvo-Pinilla E, Viaplana E, Frost L. Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge. Vaccine 2014;32:3670-4.
  45. Guthrie AJ, Quan M, Lourens CW, Audonet J-C, Minke JM, Yao J. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. Vaccine 2009;27:4434-8.

Citations

This article has been cited 1 times.
  1. Clemmons EA, Alfson KJ, Dutton JW 3rd. Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences. Animals (Basel) 2021 Jul 8;11(7).
    doi: 10.3390/ani11072039pubmed: 34359167google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.